Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer
Ru M. Wen(Stanford Medicine), James D. Brooks(Stanford University), Rosalie Nolley(Stanford University), Xiangyue Zhang(Northeastern University), Sharon J. Pitteri(Oregon Health & Science University), Fernando Jose Garcia Marques(Canary Institute of Cancer Research), Hongjuan Zhao(Stanford University), G. Edward Marti(National Institute of Standards and Technology), Edgar G. Engleman(Stanford Medicine), Aram Lyu(Fred Hutch Cancer Center), Zenghua Fan(Shandong University of Technology), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), Sarah M. Totten(University of California, Davis), Carolyn R. Bertozzi(Howard Hughes Medical Institute), Jessica C. Stark(IIT@MIT), Abel Bermudez(Canary Institute of Cancer Research), Nicholas M. Riley(University of Washington)
Cited by 41
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
|Annual Review of Pathology Mechanisms of Disease|2020|2.2k
Symbol Nomenclature for Graphical Representations of Glycans
|Glycobiology|2015|1.1k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945